Oslo, 19 February 2016

Weifa ASA: Record revenues in the fourth quarter

      ·     All time high revenues in fourth quarter 2015 of NOK 97.6 million (NOK 90.5 million)

      ·     EBITDA margin of 22.6%

      ·     Strong cash flow from operating activities

      ·     Full-year revenues rose 5.6%

      ·     Strong brands secured high market share in all categories and segments of both                  channels

      ·     Asan acquisition, adding the leading Norwegian intimate care brand to the Weifa                   portfolio

      ·     Weifa expects full-year 2016 organic revenue growth and improved EBITDA margin

Weifa ASA (OSE: WEIFA) had record revenues in the fourth quarter 2015 with
increased sales in all categories.  Total revenue for the quarter was NOK 97.6
million, representing an increase of 7.9% compared with the year earlier period.
Weifa maintained high market share in all key segments during the quarter, and
delivered continued good operations.

EBITDA was NOK 24.4 million, before NOK 2.4 million in the calculated cost of
employee options and costs in conjunction with the acquisition of Cederroth AS
and the Asan portfolio, corresponding to an adjusted EBITDA margin of 25%.

Total consumer health revenue for the year 2015 was NOK 332.5 million,
representing an increase of 5.6 percent from 2014. Full-year EBITDA came to NOK
72.9 million before option- and other costs of NOK 7.3 million, corresponding to
an adjusted EBITDA margin of 22%.

"Weifa delivered revenue growth and improved EBITDA margin through 2015 while at
the same time becoming a pure consumer health company and in the fourth quarter
announcing the acquisition of the leading intimate care brand Asan.  We have
extended our platform of flagship brands as we move into 2016 and target
continued organic growth and improved EBITDA margin", says CEO Kathrine Gamborg

Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter,
Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen
Nyberg-Hansen will represent the company. The presentation will also be webcast
live and can be accessed directly from:
http://webtv.hegnar.no/presentation.php?webcastId=29501347 or


Please find the report and presentation for the fourth quarter enclosed. The
report and presentation will also be made available on www.weifa.no.

For further information, please contact:

Kathrine Gamborg Andreassen
+47 95 17 86 80

Simen Nyberg-Hansen
+47 98 20 63 55

Weifa is Norway's leading consumer health company. We supply real value through
medicines, lifestyle products and solutions that address the essential needs of
consumers, customers and professional partners. Weifa was founded in 1940 and
now employs about 30 highly qualified people at our headquarters in Oslo. The
company has a strong position in Norway and is the market leader in pain relief,
with well-established brands such as Paracet and Ibux. We are also present in
other key areas such as dietary supplements and treatment for colds and
respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For
further information, please visit: www.weifa.no